{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T06:43:04Z","timestamp":1769236984847,"version":"3.49.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T00:00:00Z","timestamp":1628812800000},"content-version":"am","delay-in-days":346,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"RHME"},{"name":"SFCE"},{"name":"Enfants Cancers Sant\u00e9"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ejca.2020.06.024","type":"journal-article","created":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T17:50:23Z","timestamp":1597341023000},"page":"224-234","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Lymphoblastic predominance of blastic phase in children with chronic myeloid leukaemia treated with imatinib: A report from the I-CML-Ped Study"],"prefix":"10.1016","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2723-8185","authenticated-orcid":false,"given":"Deborah","family":"Meyran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaud","family":"Petit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joelle","family":"Guilhot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9522-8838","authenticated-orcid":false,"given":"Meinolf","family":"Suttorp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petr","family":"Sedlacek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eveline","family":"De Bont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2810-5758","authenticated-orcid":false,"given":"Chi Kong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Kalwak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgitte","family":"Lausen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srdjana","family":"Culic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"de Moerloose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Biondi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Millot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejca.2020.06.024_bib1","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1182\/blood-2015-06-648667","article-title":"Pediatric chronic myeloid leukemia is a unique disease that requires a different approach","volume":"127","author":"Hijiya","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2020.06.024_bib2","series-title":"Cancer incidence and survival among children and adolescents: United States SEER program 1975-1995","first-page":"46","year":"1999"},{"issue":"6","key":"10.1016\/j.ejca.2020.06.024_bib3","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/leu.2015.73","article-title":"The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries","volume":"29","author":"Hoffmann","year":"2015","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.ejca.2020.06.024_bib4","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ejca.2020.06.024_bib5","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejca.2020.06.024_bib6","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1182\/blood.V99.5.1527","article-title":"A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia","volume":"99","author":"Baccarani","year":"2002","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ejca.2020.06.024_bib7","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/leu.2017.253","article-title":"Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants","volume":"31","author":"Hehlmann","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.ejca.2020.06.024_bib8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.beha.2016.10.005","article-title":"Management of CML-blast crisis","volume":"29","author":"Hehlmann","year":"2016","journal-title":"Best Pract Res Clin Haematol"},{"issue":"13","key":"10.1016\/j.ejca.2020.06.024_bib9","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1200\/JCO.2017.75.9597","article-title":"Dasatinib in pediatric patients with chronic myeloid leukemia in chronic phase: results from a phase II trial","volume":"36","author":"Gore","year":"2018","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.ejca.2020.06.024_bib10","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1182\/blood.2019000069","article-title":"Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia","volume":"134","author":"Hijiya","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ejca.2020.06.024_bib11","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ejca.2020.06.024_bib12","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1182\/blood.V66.6.1352.1352","article-title":"Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation","volume":"66","author":"Sokal","year":"1985","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejca.2020.06.024_bib13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.leu.2402329","article-title":"Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases","volume":"16","author":"Schoch","year":"2002","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.ejca.2020.06.024_bib14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ejca.2020.06.024_bib15","first-page":"1783","article-title":"Proposals for the immunological classification of acute leukemias. European group for the immunological characterization of leukemias (EGIL)","volume":"9","author":"Bene","year":"1995","journal-title":"Leukemia"},{"issue":"282","key":"10.1016\/j.ejca.2020.06.024_bib16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"10.1016\/j.ejca.2020.06.024_bib17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/pbc.23031","article-title":"Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group","volume":"57","author":"Champagne","year":"2011","journal-title":"Pediatr Blood Canc"},{"issue":"20","key":"10.1016\/j.ejca.2020.06.024_bib18","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1200\/JCO.2010.32.7114","article-title":"Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial","volume":"29","author":"Millot","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2020.06.024_bib19","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/s41375-018-0179-9","article-title":"Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial","volume":"32","author":"Suttorp","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.ejca.2020.06.024_bib20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/ejh.12785","article-title":"Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register","volume":"98","author":"Soderlund","year":"2017","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.ejca.2020.06.024_bib21","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/annonc\/mdu490","article-title":"Differences among young adults, adults and elderly chronic myeloid leukemia patients","volume":"26","author":"Castagnetti","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2020.06.024_bib22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00277-013-1937-4","article-title":"Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV","volume":"93","author":"Kalmanti","year":"2014","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.ejca.2020.06.024_bib23","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1542\/peds.2004-2473","article-title":"Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia","volume":"116","author":"Millot","year":"2005","journal-title":"Pediatrics"},{"issue":"10","key":"10.1016\/j.ejca.2020.06.024_bib24","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.3324\/haematol.2017.170035","article-title":"Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents","volume":"102","author":"Millot","year":"2017","journal-title":"Haematologica"},{"issue":"14","key":"10.1016\/j.ejca.2020.06.024_bib25","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2020.06.024_bib26","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/pbc.24521","article-title":"Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase","volume":"61","author":"Millot","year":"2014","journal-title":"Pediatr Blood Canc"},{"issue":"2","key":"10.1016\/j.ejca.2020.06.024_bib27","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1093\/jpepsy\/jsw039","article-title":"Measuring medication adherence in pediatric cancer: an approach to validation","volume":"42","author":"Rohan","year":"2017","journal-title":"J Pediatr Psychol"},{"issue":"7","key":"10.1016\/j.ejca.2020.06.024_bib28","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00432-017-2372-z","article-title":"Factors influencing adherence in CML and ways to improvement: results of a patient-driven survey of 2546 patients in 63 countries","volume":"143","author":"Geissler","year":"2017","journal-title":"J Canc Res Clin Oncol"},{"key":"10.1016\/j.ejca.2020.06.024_bib29","article-title":"[Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia]","author":"Cayuela","year":"2019","journal-title":"Bull Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2020.06.024_bib30","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1002\/pbc.25551","article-title":"Treatment of an adolescent with chronic myeloid leukemia and the T315I mutation with ponatinib","volume":"62","author":"Nickel","year":"2015","journal-title":"Pediatr Blood Canc"},{"issue":"1","key":"10.1016\/j.ejca.2020.06.024_bib31","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/ped.13437","article-title":"Response to ponatinib before hematopoietic stem cell transplantation in a child with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"60","author":"Yamamoto","year":"2018","journal-title":"Pediatr Int"},{"issue":"22","key":"10.1016\/j.ejca.2020.06.024_bib32","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1182\/blood.2018882233","article-title":"How I treat chronic myeloid leukemia in children and adolescents","volume":"133","author":"Hijiya","year":"2019","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.ejca.2020.06.024_bib33","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/cncr.30864","article-title":"Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: cohort study of 477 patients","volume":"123","author":"Jain","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2020.06.024_bib34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejca.2019.03.020","article-title":"Favourable outcome of de novo advanced phases of childhood chronic myeloid leukaemia","volume":"115","author":"Millot","year":"2019","journal-title":"Eur J Canc"},{"issue":"12","key":"10.1016\/j.ejca.2020.06.024_bib35","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3324\/haematol.13068","article-title":"Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up","volume":"93","author":"Palandri","year":"2008","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.ejca.2020.06.024_bib36","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.6004\/jnccn.2018.0071","article-title":"Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology","volume":"16","author":"Radich","year":"2018","journal-title":"J Natl Compr Canc Netw"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920303579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920303579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:29:15Z","timestamp":1760732955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920303579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":36,"alternative-id":["S0959804920303579"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.06.024","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lymphoblastic predominance of blastic phase in children with chronic myeloid leukaemia treated with imatinib: A report from the I-CML-Ped Study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.06.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}